378. Phase I Trial of Intravenous Infusion of Onyx 015 and Enbrel in Solid Tumor Patients

Onyx 015 is an E1B deleted conditional replicating adenovirus which has demonstrated control of local regional disease in prior studies [E. Lin and J. Nemunaitis, Cancer Gene Ther 11, 643 (2004)] but demonstrates limited effect when administered as an intravenous therapeutic. We hypothesized that systemic activity may be potentiated by reduction of viral clearance related to tumor necrosis factor a (TNF|[alpha]|).